Clinical Research Protocols
Clinical Research Protocols In Ovarian Cancer
Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager, H. Lee Moffitt Cancer Center & Research Institute
(Editor's note: The following listing includes studies being performed only by
cooperative groups in the United States. For studies in other gynecologic neoplasms or for
foreign and single-institution studies, please contact PDQ.)
GOG-93 Phase III Randomized Evaluation of Adjuvant Intraperitoneal 32-P
Following Negative Second-Look Laparotomy in Patients With Stage III Epithelial Ovarian
Carcinoma (Summary last modified 11/93).
Chairman: Mahesh Amratal Varia, University of North Carolina, Chapel Hill, NC. Lead
Organization: Gynecological Oncology Group. Acceptable age range: 18 and over.
GOG-157 Phase III Randomized Study of CBDCA/TAX Administered for 3 vs 6 Courses
for Selected Stages IA-C and Stages IIA-C Ovarian Epithelial Cancer (Summary last modified
10/95).
Chairman: Robert C. Young, Fox Chase Cancer Center, Philadelphia, Pa. Lead Organization:
Gynecological Oncology Group. Acceptable age range: any age.
SWOG-9249 Phase III Randomized Study of High-Dose CBDCA/CTX With G-CSF Followed
by Standard-Dose TAX vs High-Dose TAX With G-CSF for Nonpalpable Suboptimal Stage III
Ovarian Epithelial Carcinoma (Summary last modified 09/95).
Chairman: David Samuel Alberts, Arizona Cancer Center, Tucson, Ariz. Lead Organization:
Southwest Oncology Group. Acceptable age range: adult.
GOG-158 Phase III Randomized Study of Platinum Compound and TAX in Optimal Stage
III Ovarian Epithelial Cancer: CDDP and TAX (24-Hour Infusions) vs CBDC and TAX (3-Hour
Infusion) (Summary last modified 10/95).
Chairman: Robert F Ozols, Fox Chase Cancer Center, Philadelphia, Pa. Lead Organization:
Gynecological Oncology Group. Acceptable age range: any age.
GOG-152 Phase III Randomized Study of TAX/CDDP Alone vs TAX/CDDP With Interval
Secondary Cytoreductive Surgery for Suboptimally Resected Stage III and Selected Stage IV
Ovarian Epithelial Carcinoma (Summary last modified 09/95).
Chairman: Peter Graham Rose, Case Western Reserve University, Cleveland, Ohio. Lead
Organization: Gynecological Oncology Group. Acceptable age range: any age.
GOG-114 Phase III Randomized Trial of Intravenous CDDP/CTX vs Intravenous
CDDP/TAX vs Intravenous High-Dose CBDCA Followed by Intravenous TAX/Intraperitoneal CDDP
in Patients With Optimal Stage III Ovarian Epithelial Cancer (Summary last modified
10/94).
Chairman: Robert C. Park, Walter Reed Army Medical Center, Washington, DC. Lead
Organization: Gynecological Oncology Group. Acceptable age range: any age.
GOG-90 Phase II Combination Chemotherapy With BEP (CDDP/VP-16/BLEO) as Induction
Followed by VAC (VCR/DACT/CTX) as Consolidation in Patients With Incompletely Resected
Malignant Ovarian Germ Cell Tumors (Summary last modified 10/95).
Chairman: Stephen D. Williams, Indiana University Medical Center, Indianapolis, Ind. Lead
Organization: Gynecological Oncology Group. Acceptable age range: any age.
SWOG-9106 Phase II Randomized Study of CTX/DHAD/CBDCA vs TSPA/CTX/CDDP, Each
With Autologous Bone Marrow Support, in Patients With Recurrent or Persistent Ovarian
Cancer (Summary last modified 08/94).
Chairman: Patrick J. Stiff, Stritch School of Medicine, Maywood, Ill. Lead Organization:
Southwest Oncology Group. Acceptable age range: 65 and under.
NCI-95-C-0056A Phase II Study of Continuous-Infusion Aminocamptothecin for
Advanced Epithelial Ovarian Cancer Recurrent After Paclitaxel and Either Cisplatin or
Carboplatin (Summary last modified 06/95) (NCI-95-C-0056A).
Chairman: Eddie Reed, Clinical Pharmacology Branch, NCI, Bethesda, Md. Lead Organization:
National Cancer Institute. Acceptable age range: 18 and over.
NCI-95-C-0055B Phase II Study of CTX/TAX/CDDP With G-CSF in Newly Diagnosed
Stage IIC/III/IV Ovarian Epithelial Cancer (Summary last modified 07/95).
Chairman: Elsie C. Kohn, Clinical Pharmacology Branch, NCI, Bethesda, Md. Lead
Organization: National Cancer Institute. Acceptable age range: 18 and over.
SWOG-9326 Phase II Study of HMM for Consolidation of Clinical Complete Response
in Patients With Stage III Ovarian Epithelial Cancer (Summary last modified 02/95).
Chairman: Mace L. Rothenberg, University of Texas Health Sciences Center, San Antonio,
Tex. Lead Organization: Southwest Oncology Group. Acceptable age range: adult.
GOG-9302 Phase II Study of Laparoscopic Staging in Patients With Incompletely
Staged Ovarian Cancer (Summary last modified 10/94).
Chairman: Michael David Spiritos, Abington Memorial Hospital, Abington, NY. Lead
Organization: Gynecological Oncology Group. Acceptable age range: adult.
SWOG-9324 Phase II Study of Vinorelbine for Relapsed or Refractory Epithelial
Ovarian Cancer (Summary last modified 07/95).
Chairman: Mace L. Rothenberg, University of Texas Health Sciences Center, San Antonio,
Tex. Lead Organization: Southwest Oncology Group. Acceptable age range: adult.
GOG-9202 Phase I Pilot Study of TAX/CBDCA/G-CSF With and Without IL-6 for
Untreated Suboptimal Stage III/IV Ovarian Epithelial or Primary Peritoneal Cancer (Summary
last modified 11/95).
Chairman: Robert F. Ozols, Fox Chase Cancer Center, Philadelphia, Pa. Lead Organization:
Gynecological Oncology Group. Acceptable age range: 18 and over.
GOG-9203 Phase I Study of TAX/VP-16 With and Without G-CSF in Patients With
Refractory Ovarian Cancer (Summary last modified 08/94).
Chairman: Gini Fleming, University of Chicago Hospital, Chicago, Ill. Lead Organization:
Gynecological Oncology Group. Acceptable age range: 18 and over.
GOG-9201 Chairman: Maurie Markman, Cleveland Clinic Foundation Hospital,
Cleveland, Ohio. Lead Organization: Gynecological Oncology Group. Acceptable age range: 18
and over.
Legend for Abbreviations:
GOG = Gynecologic Oncology Group
NCI = National Cancer Institute
SWOG = Southwest Oncology Group
Back to Cancer Control Journal Volume 3 Number 2